AUS
NZ
UK
CA
USA
IND
Healthcare
Avacta Group Strengthens Leadership with Oncology Expert Michelle Morrow
October 15, 2024 08:13 AM BST| By Team Kalkine MediaKey Points,:,Dr. Michelle Morrow, an experienced oncology expert, has been appointed as Chief Scientific Officer at Avacta Group.,She brings nearly 20 years of experience in oncology therapeutics and antibody research, including leadership roles at i...
_10_15_2024_12_58_09_224155.jpg)
Lundbeck Acquires Longboard Pharmaceuticals in $2.6bn Deal to Bolster Neurological Pipeline
October 15, 2024 12:00 AM BST| By Team Kalkine MediaHighlights:,Strategic Acquisition,: Lundbeck will acquire Longboard Pharmaceuticals for $2.6 billion, strengthening its portfolio of treatments for neurological diseases.,Promising Drug Addition,: Longboard's lead asset, bexicaserin, has shown promis...
Oxford BioDynamics Faces Urgent Need for New Funding Amid Share Plunge
October 14, 2024 12:13 PM BST| By Team Kalkine MediaHighlights:,New Funding Needed,: Oxford BioDynamics announced that it requires additional funding by Q1 2025 to maintain operations.,Cost-Cutting Initiatives,: Senior staff will receive 25% of their pay in shares as part of efforts to conserve cash.,...
Mendell Helium Sells Plant-Based Health and Wellness Business to Orsus Therapeutics
October 14, 2024 12:13 PM BST| By Team Kalkine MediaHighlights:,Strategic Sale,: Mendell Helium sells its plant-based health and wellness business to Orsus Therapeutics, retaining a 28% stake.,Helium Focus,: Mendell shifts its business direction towards helium assets in North America.,Future Growth,:...
Positive Outcomes in Phase III Nasal Polyps Study Highlighted by GSK
October 14, 2024 08:24 AM BST| By Team Kalkine MediaHighlights:,GSK PLC reports positive results from two phase III clinical trials (ANCHOR-1 and ANCHOR-2) for its treatment depemokimab targeting chronic rhinosinusitis with nasal polyps (CRSwNP).,Patients treated with depemokimab demonstrated signific...
Verici Dx Postpones ‘Tutivia’ Revenue as Medicare Approval Drags On
October 11, 2024 01:01 PM BST| By Team Kalkine MediaHighlights:,CMS Coverage Delay,: Verici Dx’s Tutivia test faces a delay in Medicare approval, pushing revenue recognition to 2025.,Financial Stability,: Verici Dx maintains a $6.1 million cash balance and a disciplined cost-control approach, aligning...
SkinBioTherapeutics Acquires Bio-Tech Solutions Ltd for £1.25 Million
October 11, 2024 09:27 AM BST| By Team Kalkine MediaHighlights,SkinBioTherapeutics has acquired Bio-Tech Solutions Ltd for £1.25 million.,The deal will be financed through a combination of a £950,000 loan from a shareholder, a subscription for new shares raising £250,000, and the use of the company's...
Sanofi in Talks with Clayton, Dubilier & Rice Over Potential Opella Sale
October 11, 2024 12:00 AM BST| By Team Kalkine MediaHighlights:,Sanofi in Talks with CD&R,: Sanofi is discussing the sale of a 50% stake in its consumer healthcare arm, Opella, with Clayton, Dubilier & Rice.,Focus on Core Business,: Divesting Opella aligns with Sanofi’s plan to concentrate on innovati...
ProBiotix Health Enters New Partnership with Mexico-Based Raff
October 10, 2024 11:01 AM BST| By Team Kalkine MediaKey Points:,Strategic Partnership,: ProBiotix teams up with Raff, a key player in the Mexican dairy and nutraceutical sectors.,Market Potential,: Mexico’s high cardiovascular disease rates present a lucrative opportunity for health-focused probiotic...
Avacta Group Presents Breakthrough Preclinical Data on Pre|CISION™ Platform at 2024 EORTC-NCI-AACR Symposium
October 10, 2024 10:46 AM BST| By Team Kalkine MediaKey Points:,AVA6103,, a new peptide drug conjugate (PDC), targets Topoisomerase I inhibitors to tumor cells, reducing toxicity to healthy tissues and showing promising tumor inhibition.,Affirmer® Drug Conjugates,, a new class of biotherapeutics, offe...
GSK Reaches $2.2bn Settlement in Zantac Litigation in the United States
October 10, 2024 09:43 AM BST| By Team Kalkine MediaHighlights:,GSK PLC has agreed to pay up to $2.2 billion to settle approximately 80,000 US lawsuits related to its heartburn medication, Zantac.,The settlement resolves 93% of state court cases, while GSK maintains there is no evidence linking Zantac...
FTSE 100 Highlights: Gains Lost; GSK Sees Increase on $2.2bn Zantac Settlement
October 10, 2024 09:17 AM BST| By Team Kalkine MediaHighlights:,Vistry Group PLC faced significant losses, becoming one of the FTSE 100's biggest fallers after a profit warning.,GSK PLC shares surged on news of a settlement regarding Zantac lawsuits, lifting the index in early trading.,The UK housing...
A positive outcome from the AGM has prompted a rise in the shares of Fusion Antibodies
October 08, 2024 12:19 PM BST| By Team Kalkine MediaHighlights:,Fusion Antibodies PLC reports significant revenue growth, with expected first-half revenues reaching £1.2 million, more than double the previous year’s figure.,The company achieves a notable improvement in gross margin, rising to 29% comp...
ProBiotix Health Shares Q3 2024 Trading Update with Continued Growth in Sales and Profitability
October 08, 2024 08:51 AM BST| By Team Kalkine MediaHighlights,ProBiotix reported a 39% increase in sales, reaching £1.525 million compared to £1.099 million in 2023.,A product launch on Amazon and in 2,000 Target stores is driving strong growth in the US market, with more sales pushes planned for Q4...
AstraZeneca has acquired a license from CSPC in China for a cholesterol treatment
October 07, 2024 03:32 PM BST| By Team Kalkine MediaHighlights:,AstraZeneca has acquired a license for a novel cholesterol-lowering drug, YS2302018, from CSPC Pharmaceutical for an initial payment of $100 million.,The drug targets the formation of lipoproteins linked to coronary artery disease and str...
Futura Medical Secures $5 Million Milestone Payment Following US Launch of Eroxon
October 07, 2024 11:46 AM BST| By Team Kalkine MediaHighlights:,Milestone Payment Secured,: Futura Medical received a $5 million payment following the US launch of its over-the-counter erectile dysfunction gel, Eroxon.,Significant Market Opportunity,: Analysts project peak Eroxon sales of £176 million...
ValiRx Subsidiary Partners with BioRep to Enhance Drug Screening Services
October 07, 2024 08:56 AM BST| By Team Kalkine MediaKey Points:,Inaphaea BioLabs has executed a co-marketing agreement with BioRep to enhance drug screening services and patient-derived cells.,BioRep will provide backup sample storage and logistics, along with molecular biology services in mainland Eu...
Faron Pharmaceuticals to Host Capital Markets Day on 22 October 2024. What’s Expected?
October 07, 2024 08:37 AM BST| By Team Kalkine MediaKey Points:,Faron Pharmaceuticals will host a Capital Markets Day on October 22, 2024, featuring key presentations from leading experts.,The agenda includes discussions on the company’s strategy, updated clinical data for bexmarilimab, and market ass...
Life Science REIT Backed by Berenberg's Optimistic Forecast, UK Growth Expected
October 04, 2024 03:32 PM BST| By Team Kalkine MediaHighlights:,Strong growth potential:,Berenberg reaffirms its "buy" rating for Life Science REIT, highlighting a price target of 57p per share.,Undervalued stock:,The company trades at a 46% discount to NAV, offering a 5% dividend yield with strong le...
China and Southeast Asia Hurdles Lead to Revenue Warning from Eco Animal Health
October 01, 2024 11:57 AM BST| By Team Kalkine MediaHighlights:,Eco Animal Health warns full-year revenues will fall below expectations due to challenges in China and Southeast Asia.,Strong performance in Brazil, India, and the US bolstered the company’s market share, with Aivlosin driving growth.,The...
